

RS Research Starts Clinical Development of Novel Targeted Chemotherapy Drug Candidates

Business Model

Active Targeting
with peptide, protein, mab

Proprietary Nano-carrier
High drug loading capacity


Prodrugs
from clinically proven chemo agents

Superior Results
Improved side effect profile
Increased efficacy



2 Novel Platforms
Protected with
worldwide patents



Timeline



Drug Delivery Platform: Sagitta®

The platforms carry multiple copies of the drug and a targeting moiety for directing the assembly to tumor tissue.


Both platforms consist of highly flexible carriers: Size, linker, drug(s) and targeting moiety can all be rationally optimized.




Staining Results of 67 NSCLC Patients

Positive biomarker expression for both adeno and squamous cell carcinoma is:

70%



We Use Active Targeting (Peptide/Mab)






Active targeting moieties recognize cell surface receptors

Drug carrier is internalized via endocytosis

Drug is released via cleavage of an enzyme sensitive linker




Leading Candidate RS-0139 Shows Improved Pharmacokinetics and Favorable Toxicity




RS Research Candidates Show Superior Efficacy on Tumors and Exceptional Effect on Survival


RS-0139 on NSCLC




RS-0735 on Pancreatic CA



RS-0139 on Breast CA



RS-0139 on NSCLC Model II



RS Research's lyophilized cytotoxic GMP clinical batch production plant



Drug Candidate	Research	Preclinical	IND Approval	Clinical	Platform	Proposed Indication
RS-0139	✓	✓	✓	STARTING PHASE-1	I	NSCLC CA Breast CA Prostate CA
RS-0337	✓	✓	✓		II	Breast CA
RS-0461	✓	✓	✓		II	Ovarian CA
RS-0625	✓	✓	✓		I	Ovarian CA
RS-0735	✓	✓	✓		I	Pancreas CA

We target multiple cancer indications with our plug & play methodology

Sena Nomak
 Co-Founder & COO
 sn@rsresearch.net
 +90 (530) 760 6762

Cure with a smile

Prof. Rana Sanyal
 Co-Founder & CSO
 rs@rsresearch.net
 +90 (536) 206 24 40